Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087103 | 0.83 | MEN1 (0.42) | MEN1KMT2ACYP2C9CYP3A4TDP1 | |
| SCHEMBL2583091 | 0.74 | CYP2C9 (1.00) | MEN1KMT2ACYP2C9CYP3A4TDP1 | |
| SCHEMBL30516131 | 0.74 | CYP2C9 (1.00) | MEN1KMT2ACYP2C9CYP3A4TDP1 | |
| SCHEMBL25149031 | 0.72 | LMNA (1.00) | MEN1KMT2ACYP2C9CYP3A4LMNA | |
| SCHEMBL30516134 | 0.71 | MEN1 (0.58) | MEN1KMT2ACYP2C9CYP3A4TDP1 | |
| SCHEMBL20211622 | 0.71 | MEN1 (0.58) | MEN1KMT2ACYP2C9CYP3A4TDP1 | |
| SCHEMBL6053692 | 0.69 | CYP2C9 (0.78) | MEN1KMT2ACYP2C9CYP3A4TDP1 | |
| SCHEMBL14426486 | 0.69 | CYP2C9 (0.78) | MEN1KMT2ACYP2C9CYP3A4KDM4E | |
| SCHEMBL25148953 | 0.68 | LMNA (0.87) | MEN1KMT2ACYP2C9CYP3A4LMNA | |
| SCHEMBL1017795 | 0.68 | CYP3A4 (0.89) | MEN1KMT2ACYP2C9CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337018-A1 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2015-11-26 | — | — | US | claimed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | claimed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | claimed |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-9879058-B2 | Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders | UNIVERSIDAD ANDRES BELLO (CL) | 2018-01-30 | — | — | US | disclosed |
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-9550828-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550828-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150337018-A1 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2015-11-26 | — | — | US | disclosed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | disclosed |
| US-20150093391-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150093391-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | BOISE STATE UNIVERSITY (US) | 2015-04-02 | — | — | US | disclosed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196973-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | IL6, OGFRL1, OGFR | MEN1 2377/4885KMT2A 1658/4885CYP2C9 4879/4885 |
| US-20150093391-A1 | ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS | IL6, OGFRL1, OGFR | MEN1 2377/4885KMT2A 1658/4885CYP2C9 4879/4885 |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | IL6, OGFRL1, OGFR | MEN1 2377/4885KMT2A 1658/4885CYP2C9 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.